Condition
Frown Lines
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
60%
3 of 5 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04763265Phase 2CompletedPrimary
Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
NCT03786770Phase 2CompletedPrimary
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
NCT01801826CompletedPrimary
A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device
NCT01808742CompletedPrimary
Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device
NCT01797094Phase 3Completed
BOTOX® in the Treatment of Upper Facial Lines in Japan
Showing all 5 trials